Ian Somaiya

Matthew Keeler

Raj Denhoy

Steve Lichtman

- Leap Therapeutics (Nasdaq: LPTX) will present **final clinical results** from Part B of the DeFianCe study, a Phase 2 trial of its drug candidate **sirexatamab (DKN-01)**, at the European Society for Medical Oncology (ESMO) Congress 2025.  **[1509745_20250925NE82443:0]** 
- The data pertains to sirexatamab in combination with bevacizumab and chemotherapy for patients with **advanced microsatellite stable (MSS) colorectal cancer**.  **[1509745_20250925NE82443:0]** 
- The presentation is scheduled for a Mini Oral Session on **Sunday, October 19, 2025, at 4:05 p.m. CEST**.  **[1509745_20250925NE82443:0]** 
- The company also stated its plan to reduce clinical and operational activities, conserve cash, and explore strategic alternatives, including potentially **selling or partnering sirexatamab or FL-501**.  **[1509745_20250925NE82443:1]**

LEAP THERAPEUTICS (LPTX)